09 May 2018 --- Dutch-based Royal DSM this week issued its full Q1 2018 results, which are in line with the previously announced preliminary figures for Q1 2018 on 12 April 2018. Highlights include continued strong organic sales growth in underlying business estimated at 11 percent, additional temporary vitamin price benefit estimated at €165 million (US$195.3 million) on Adjusted EBITDA and total Adjusted EBITDA up 56 percent and Net profit up 122 percent to €331 million (US$391.8 million).
